Fidelio acquires Indical Bioscience

April 5, 2018

Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.

The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.

Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.

Recent news

Fidelio Capital acquires Premune’s shares in Ne…

We are pleased to announce that, effective 24 November 2020, Fidelio Capital AB (“Fidelio”) has completed the acquisition of Premune AB’s (“Premune”) shares in Nextmune. Through the transaction, Fidelio will increase its ownership in Nextmune and become the majority owner.

Read more

Indical acquires Afosa to expand into the compani…

Indical has acquired Afosa GmbH, a leading provider of ELISA diagnostics products to the companion animal sector, based in Germany. Indical has a strong diagnostics portfolio focused on production animals, which is built on more than twenty years of research

Read more

BoNea and Akevo join Nabo

Nabo acquires BoNea and Akevo – two property management companies based in Sweden. BoNea and Akevo offer financial management services to 250 tenant-owner associations. Read the full press release here (Swedish).

Read more